Combination Therapy for Extreme Drug-Resistant Acinetobacter baumannii: Ready for Prime Time?

about

In Vitro Activity of the Novel Antimicrobial Peptide Dendrimer G3KL against Multidrug-Resistant Acinetobacter baumannii and Pseudomonas aeruginosa.Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges.

P2860

Q36290577-D4E12368-7A23-4BA9-868F-7AF0D0338A91 Q39038590-074E14F1-92B4-45DE-85A1-A538C0E0B2EC

P2860

Combination Therapy for Extreme Drug-Resistant Acinetobacter baumannii: Ready for Prime Time?

Item

http://www.wikidata.org/entity/Q43202091

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Combination Therapy for Extrem ...... umannii: Ready for Prime Time?

@en

Combination Therapy for Extrem ...... umannii: Ready for Prime Time?

@nl

type

Item

label

Combination Therapy for Extrem ...... umannii: Ready for Prime Time?

@en

Combination Therapy for Extrem ...... umannii: Ready for Prime Time?

@nl

prefLabel

Combination Therapy for Extrem ...... umannii: Ready for Prime Time?

@en

Combination Therapy for Extrem ...... umannii: Ready for Prime Time?

@nl

P1476

Combination Therapy for Extrem ...... umannii: Ready for Prime Time?

@en

P2093

Brad Spellberg

http://www.w3.org/2001/XMLSchema#string

P2860

Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis

Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients

Effectiveness of tigecycline-based versus colistin- based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis.

White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens

The FDA reboot of antibiotic development.

Pharmacodynamics of levofloxacin in a murine pneumonia model of Pseudomonas aeruginosa infection: determination of epithelial lining fluid targets

A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline.

Clinical outcomes of carbapenem-resistant Acinetobacter baumannii bloodstream infections: study of a 2-state monoclonal outbreak.

Risk factors and mortality of patients with nosocomial carbapenem-resistant Acinetobacter baumannii pneumonia.

The value of single-pathogen antibacterial agents.

P304

1332-1334

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1097/CCM.0000000000001029

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Robert A Bonomo

P577

2015-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25978159

http://www.w3.org/2001/XMLSchema#string

P921

Acinetobacter baumannii

P932

4620434

http://www.w3.org/2001/XMLSchema#string

Combination Therapy for Extreme Drug-Resistant Acinetobacter baumannii: Ready for Prime Time?

about

P2860

P2860

Combination Therapy for Extreme Drug-Resistant Acinetobacter baumannii: Ready for Prime Time?

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932